Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14.

  title={Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14.},
  author={Sheryl A Kingsberg and Stanley E. Althof and James A Simon and Andrea Bradford and Johannes Bitzer and Joana Carvalho and Kathryn E. Flynn and Rossella Elena Nappi and Jennifer Barsky Reese and Roya L Rezaee and Leslie R Schover and Jan L Shifrin},
  journal={The journal of sexual medicine},
  volume={14 12},

Figures and Tables from this paper

Female Sexual Dysfunction: Pharmacologic and Therapeutic Interventions.
Female sexual dysfunction is often overlooked in clinical practice; however, there are effective medical and psychological options for management.
Female Sexual Dysfunction
Female sexual dysfunction (FSD) represents an enigmatic yet complex set of disorders in this millennia, wherein significant changes have been implemented in defining, categorizing and managing these
Screening and Management of Female Sexual Dysfunction During the Second Half of Life
Screening of FSD should be based on clinical history and the use of screening tools such as the 14-item Changes in Sexual Functioning Questionnaire, the 19-item Female Sexual Function Index (FSFI-19), or the Decreased Sexual Desire Screener.
Sexual Performance Anxiety.
  • R. Pyke
  • Psychology
    Sexual medicine reviews
  • 2019
What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?
The chronic progressive condition formerly known as vulvovaginal atrophy (VVA) was recently renamed genitourinary syndrome of menopause (GSM) to indicate the constellation of urogenital signs and symptoms associated with aging and hormonal changes.
Hypoactive sexual desire disorder (HSDD) is not “female erectile dysfunction (ED)”: challenges with the characterization of HSDD in women based on a systematic literature review
HSDD and ED are distinct conditions affecting different phases of the sexual response model, and thus require clear and unique clinical characterization and adequate communication between the health care professional and patient for appropriate diagnosis, management and treatment.


Psychological and interpersonal dimensions of sexual function and dysfunction.
The salient psychological and interpersonal issues contributing to sexual health and dysfunction are highlighted, an etiological model for understanding the evolution and maintenance of sexual symptoms is offered, and recommendations for clinical management and research are offered.
Women's sexual desire and arousal disorders.
Specific recommendations for the assessment and treatment of women's desire, arousal, and orgasm disorders are forwarded; however, more research into these domains is needed.
Hypoactive sexual desire in women
Low sexual desire is the most prevalent sexual problem in women and should be assessed and treated by healthcare professionals, and there are only modest evidence-based nonpharmacologic treatment options and no approved pharmacologic options.
Female sexual dysfunction: potential for pharmacotherapy.
There is no evidence to suggest that the majority of women correlate their sexual enjoyment and satisfaction with numbers of orgasms or even the likelihood of orgasm during a given sexual interaction, so any drug coming through the regulatory agency in the US will need to follow these recommendations.
Advances in pharmacotherapy for treating female sexual dysfunction
The paper reports the most recent advances in pharmacotherapy for women taking into account the biopsychosocial model and discusses the potential use of on-demand combined hormonal (testosterone) and non-hormonal (buspirone or sildenafil) treatments to address possible neurophysiological profiles of women.
Definitions of women's sexual dysfunction reconsidered: Advocating expansion and revision
Based on the review of existing evidence-based research, many modifications to the definitions of women's sexual dysfunctions are recommended and a recommendation is made that all diagnoses be accompanied by descriptors relating to associated contextual factors and to the degree of distress.
Managing female sexual dysfunction.
  • J. Buster
  • Psychology
    Fertility and sterility
  • 2013
Drugs in early clinical development for the treatment of female sexual dysfunction
The aim of this paper is to provide the latest data on pharmacological treatments for FSD currently in Phase I and II clinical trials, withications in early phase trials show promise for the treatment of FSD.
Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment.
Female sexual arousal disorders.
Definitions of the different types of FSAD are given, their aetiology, prevalence and comorbidity with somatic and psychological disorders, as well as to discuss different medical and psychological assessment and treatment modalities are given.